

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/13773993>

Synthesis, Activity, and Structure–Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · FEBRUARY 1998

Impact Factor: 5.45 · DOI: 10.1021/jm9704964 · Source: PubMed

CITATIONS

223

READS

16

11 AUTHORS, INCLUDING:



Gerardo Byk

Bar Ilan University

68 PUBLICATIONS 1,816 CITATIONS

SEE PROFILE



Caroline Dubertret

Hôpital Louis-Mourier – Hôpitaux Universitai...

68 PUBLICATIONS 1,573 CITATIONS

SEE PROFILE



Bertrand Schwartz

French National Institute for Agricultural Res...

23 PUBLICATIONS 1,973 CITATIONS

SEE PROFILE



Daniel Scherman

Université René Descartes - Paris 5

409 PUBLICATIONS 16,372 CITATIONS

SEE PROFILE

Synthesis, Activity, and Structure–Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer

Gerardo Byk,^{*,†} Catherine Dubertret,[†] Virginie Escriou,[†] Marc Frederic,[†] Gabrielle Jaslin,[†] Ravi Rangara,[†] Bruno Pitard,[†] Joel Crouzet,[‡] Pierre Wils,[†] Bertrand Schwartz,[†] and Daniel Scherman^{*,†}

Gencell/ Rhone-Poulenc Rorer, UMR-133 RPR-CNRS, and Vector Development 13, Quai Jules Guesde B.P. 14, 94403-Vitry sur Seine, France

Received July 30, 1997

We have designed and synthesized original cationic lipids for gene delivery. A synthetic method on solid support allowed easy access to unsymmetrically monofunctionalized polyamine building blocks of variable geometries. These polyamine building blocks were introduced into cationic lipids. To optimize the transfection efficiency in the novel series, we have carried out structure–activity relationship studies by introduction of variable-length lipids, of variable-length linkers between lipid and cationic moiety, and of substituted linkers. We introduce the concept of using the linkers within cationic lipids molecules as carriers of side groups harboring various functionalities (side chain entity), as assessed by the introduction of a library composed of cationic entities, additional lipid chains, targeting groups, and finally the molecular probes rhodamine and biotin for cellular traffic studies. The transfection activity of the products was assayed *in vitro* on Hela carcinoma, on NIH3T3, and on CV1 fibroblasts and *in vivo* on the Lewis Lung carcinoma model. Products from the series displayed high transfection activities. Results indicated that the introduction of a targeting side chain moiety into the cationic lipid is permitted. A primary physicochemical characterization of the DNA/lipid complexes was demonstrated with this leading compound. Selected products from the series are currently being developed for preclinical studies, and the labeled lipopolyamines can be used to study the intracellular traffic of DNA/cationic lipid complexes.

Introduction

A great number of genes for which abnormal expression is linked to human diseases are being cloned and identified. The ability to express such genes in humans might allow the prevention or even the cure of many important human diseases, which are either treated poorly or untreatable by the present therapies. However, insufficient transgene expression *in vivo* impairs the development of effective gene therapy. Therefore, it would be of interest to develop compositions and delivery methods for gene therapy that provide a high level of transcription of the transgene and/or expression in a variety of cell and tissue types. Synthetic DNA delivery agents are of crucial interest for gene therapy as an alternative to viral vectors, since they display potentially less risks in terms of immunogenicity and propagation.^{1,2} Thus, gene transfer using synthetic compounds is a rapidly increasing field.³ So far the largest family of such agents is based on cationic lipids able to self-associate and form complexes with DNA inferring a compacted state to the plasmid. In the recent years, a variety of cationic lipids for gene transfer have been described.^{3–8} Cationic lipids are composed of three elements as outlined in Figure 1.

Cationic lipids for DNA delivery can be classified into three different groups: (1) *Quaternary ammonium salt lipids* in which a lipid is linked through a spacer to a




Figure 1. General composition of a cationic lipid for DNA delivery.




Figure 2. Representative cationic lipids for DNA delivery.

quaternary ammonium salt; examples of this class are DDAB and DMRIE^{2,8} (see Figure 2). These cationic lipids have increased transfection activity when coformulated with the neutral lipid DOPE.⁹ (2) *Lipoamines* in which a lipid is linked through a spacer to an amine or to a polyamine; examples of this class are DC-Chol⁴ and DOGS⁵ (the first coformulated with DOPE). (3) *Cationic lipids containing a quaternary ammonium salt*

* To whom correspondence should be addressed. Phone: 33 1 55713779. Fax: 33 1 55713796. E-mail: gerardo.byk@rhone-poulenc.com or daniel.scherman@rhone-poulenc.com.

[†] UMR-133 RPR-CNRS.

[‡] Vector Development 13




Figure 3. Structure–activity relationship studies on cationic lipids.

and a lipoamine; examples of this class are DOSPA⁶ and DLRIE,^{2,8} which combine the use of amines and a quaternary ammonium salt in the same molecule, and are also proposed in association with DOPE or other neutral lipids for transfection activity.

The main efforts of recent works have been focused on modifications of the lipid chains and of the substituents on the quaternary ammonium salts. These efforts led to the recently described DMRIE and DLRIE which are being studied in clinical trials. In the second and third groups, the polyamine component has usually been carboxyspermine as described by J. P. Behr in DOGS⁵ and used also by others.⁶ In contrast, modifications of the polyamine component have not been extensively reported (during completion of the manuscript for this paper, some geometrically differing polyamines have been described⁷ but with a limited synthetic and diversity scope, as polyamines remained unfunctionalized and were directly linked to lipid-forming amide bonds). Similarly, replacement of the quaternary ammonium salt by other cationic entities and the introduction of different linkers have not been extensively and systematically studied. Ruyschaert and colleagues¹⁰ have demonstrated that basic moieties such as amidines might confer a transfection activity when introduced into a lipid. We and others^{11,12} have also used this concept to achieve increased transfection activity.

To obtain novel tools for increased *in vitro* and *in vivo* gene delivery, for tissue targeting and also for cellular traffic studies, we have implemented a step by step strategy by introduction of systematic modifications into the cationic lipid backbone. Subsequently, we have introduced a novel element, a “side chain entity”, on the linker. Modifications were followed by *in vitro* biological assays. Molecules emerging from intermediate steps and having increased gene delivery properties as well as chemical versatility were selected as starting precursors for further structure–activity relationship (SAR) studies (see Figure 3). It was further tested to determine if the introduction of a “side chain entity” led to any transfection activity.

Our strategy included SAR studies focused on the following modifications: (1) introduction of a library of geometrically differing polyamines as the cation component, (2) introduction of a library of linkers with differing lengths, (3) modification of linker length and polyamine geometry, (4) variation in the length of the lipid moiety, (5) introduction of a novel “side chain entity” element into cationic lipids on the linker position,

the group being either (a) a library of aliphatic, aromatic, cationic, or targeting moieties or (b) a library of molecular probes for vector trafficking studies.

Finally, we have assessed the transfection activity of several selected products in the *in vivo* Lewis lung carcinoma tumor model.

Results and Discussion

(1) Introduction of a Library of Geometrically Differing Polyamines as the Cation Component: Synthesis and *In Vitro* Transfecting Activity. To study the impact of polyamine polymorphism on gene transfer by lipopolyamines, we chose to prepare geometrically differing functionalized polyamines using the lipopolyamine DOGS⁵ as a starting model. To avoid the tedious multistep reactions necessary to obtain monofunctionalized polyamines by solution methods,¹³ we have developed a solid-phase synthesis which allowed a rapid preparation of a great number of differing monofunctionalized polyamines.¹⁴

In this approach, the alkylating reagent is covalently attached to the polymeric support through esterification. The principle is the use of solid-phase synthesis to obtain a “high dilution effect” at the proximity of the alkylating reagent, which prevents polyalkylation of the polyamine once the first alkylation has taken place. The symmetrical polyamine reacts with the alkylating reagent on the solid phase to yield an unsymmetrically monofunctionalized polyamine attached to the support.


This method allowed the easy access to unsymmetrically monofunctionalized polyamines in one step starting from their symmetrical counterparts. The resulting products are fully protected by addition of exceeding di-*tert*-butyl dicarbonate or other protecting groups.¹⁵ The building blocks are cleaved from the acid-sensitive 2-chlorotrityl chloride support with trifluoroethanol to give the fully protected functionalized polyamines bearing an acid function suitable for subsequent coupling with the lipid and amino acid component using BOP reagent.¹⁶ This method seems to be very convenient for the synthesis of unsymmetrically monofunctionalized polyamines which could not be easily synthesized by conventional methods (such as branched shaped polyamines). We have thus obtained “linear-shaped”, “globular-shaped”, “T-shaped”, and “branched-shaped” lipopolyamines (see Figure 4 and Table 1). The versatility of using amino acids as linkers has been demonstrated so far for other applications. Therefore, for the first study, Gly was chosen as linker between the functionalized polyamine and the lipid moiety.

The obtained lipopolyamines were assayed *in vitro* on human carcinoma Hela cells. Results presented in Table 1 show that although all the lipopolyamines displayed a high level of transfection efficiency in this model, the linear RPR-120535 leads to the highest level of luciferase expression, followed by the branched RPR-120525, the T-shaped RPR-126096, and finally the globular lipopolyamine. It should be pointed out that no significant differences in the cytotoxicity of the products could be observed by protein quantification (data not shown). Thus differences in activities are likely attributed to structural differences. From this first study emerged the linear lipopolyamine RPR-120535, which was used for further *in vitro* SAR studies.

Table 1. Impact of Polyamine Geometry on Expression of Luciferase in Transfected Human Hela Cells (see the Experimental Section)

N° RPR	Head Geometry	R ₁	R ₂	m	X	R ₅	Hela cells [RLU]*
120525	Branched		H	1	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	5.8 10 ⁵
120528	Globular		H	1	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	1.3 10 ⁵
126096	« T » shape			1	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	5.5 10 ⁵
120535	linear		H	1	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	2.4 10 ⁶

* RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (for substituents refer to the general structure in Figure 4).

**Figure 4.** Solid phase synthesis of geometrically differing lipopolyamines.

(2) Introduction of Variable-Length Linkers.

The linker in RPR-120535 contains five atoms between the polyamine and the lipid. To refine the transfection activity, we have introduced linkers with various numbers of atoms. The linker was modulated from two atoms in RPR-120534 up to nine atoms in RPR-128506. The method used for the synthesis was the same as for the first series (see the Experimental Section).

The products were tested on Hela cells, and the results in Table 2 suggest that all of the products possess a similar level of transfection efficiency precluding a clear selection. Additionally, no significant difference in the cytotoxicity of the products could be observed (data not shown). Thus, for chemical feasibility and versatility reasons, we selected RPR-120534 and

RPR-120535 for further studies, which contain two and five atoms between the polyamine and the lipid, respectively.

(3) Modification of Linker Length and Polyamine Geometry. To further establish a clear activity ranking for our family of cationic lipids, we have synthesized cationic lipids containing geometrically differing polyamines and with two or five atoms linker (containing Gly or not), and we have compared their efficiency to transfect NIH3T3 mouse fibroblast cells instead of Hela cells, as in the latter no influence of the linker length could be detected (see Table 3).

Results obtained with the NIH3T3 fibroblasts suggest that a longer linker increases in general the gene delivery activity (see Table 3). This effect was significant for the globular couple 120527/120528 (the latter being about 20-fold more active) and for the linear-shaped couple 120535/12534 (25-fold increase in activity), and this effect was weak for the branched-shaped couple 120526/120525. The globular-shaped RPR-120527 and 120528 displayed lower transfection activities as compared to the linear, T-shaped, or branched spermine derivatives. These lower activities can be attributed in part to decreased pK values of the different amines in the globular compounds, since the shorter ethylene chains between the amines in the globular lipids RPR-120527 and 120528 probably have an impact on the total positive charges available for binding to DNA at physiological conditions, when compared with propylene or tetramethylene in spermine derivatives.

In this study RPR-120535, which includes a linker of five atoms and a linear polyamine, proved to be the most active product in vitro on HeLa human carcinoma cells

Table 2. Impact of Linker Length on Expression of Luciferase in Transfected Human Hela Cells (See the Experimental Section)

N° RPR	R ₁	R ₂	m	N° of atoms of linker	X	R ₅	Hela cells [RLU]*
120534		H	1	2	-	(CH ₂) ₁₇ CH ₃	2.6 10 ⁶
122786		H	3	4	-	(CH ₂) ₁₇ CH ₃	1.5 10 ⁶
120535		H	1	5	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	2.4 10 ⁶
128506		H	1	9	NH(CH ₂) ₅ CO	(CH ₂) ₁₇ CH ₃	3.5 10 ⁶

^a RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (for substituents refer to the general structure in Figure 4).

Table 3. Structure–Activity Relationship Studies on Linker Length/Polyamine Geometry^a

N° RPR	R ₁	R ₂	Head Geometry	X	R ₅	NIH3T3 cells [RLU]*
120526		H	Branched	-	(CH ₂) ₁₇ CH ₃	5.9 x10 ⁷
120525		H	Branched	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	6.8 10 ⁷
120527		H	Globular	-	(CH ₂) ₁₇ CH ₃	1.5 10 ⁶
120528		H	Globular	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	2.0 10 ⁷
120534		H	Linear	-	(CH ₂) ₁₇ CH ₃	2.0 10 ⁶
120535		H	Linear	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	5.4 10 ⁷

^a Impact on expression of luciferase in transfected mouse fibroblasts NIH3T3 cells. *RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (for substituents refer to the general structure in Figure 4).

Table 4. Impact of the Length of the Lipid on Expression of Luciferase in Transfected Human Hela and Mouse Fibroblasts NIH3T3 Cells

N° RPR	R ₁	R ₂	X	R ₃	Hela cells [RLU]*	NIH3T3 cells [RLU]*
120535		H	NHCH ₂ CO	(CH ₂) ₁₇ CH ₃	8.9 10 ⁵	4.4 10 ⁷
122766		H	NHCH ₂ CO	(CH ₂) ₁₃ CH ₃	1.1 10 ⁵	2.7 10 ⁶
122774		H	NHCH ₂ CO	(CH ₂) ₁₂ CH ₃	2.3 10 ⁴	2.0 10 ⁵
122767		H	NHCH ₂ CO	(CH ₂) ₁₁ CH ₃	0	2.6 10 ³

* RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (for substituents refer to the general structure in Figure 4).

and NIH3T3 mouse fibroblasts. In comparative studies, this lead compound RPR120535 was found to possess transfection efficiency similar to that of commercially available Transfectam and Lipofectamine on cell lines such as NIH3T3, 3LL mouse Lewis lung carcinoma, Caco-2 human colon carcinoma, and primary rabbit smooth muscle cells (in ± 2 –5-fold variation range depending on cell type, data not shown). The gene transfer efficiency and the chemical versatility conferred to the cationic lipid by the use of an α -amino acid as linker in RPR-120535 prompted us to use the latter as a model for further SAR studies.

(4) Variable Length of the Lipid Moiety. The last classical element of the backbone to be studied was the lipid chain. Previous works have shown that a single fatty chain or cholesteryl in the absence of colipid DOPE prevented transfection activity and conferred undesirable cytotoxicity in lipopolyamines.⁹ The optimal length of the double fatty chain might vary for different products. We have introduced lipid chains containing from 12 to 18 carbons and assayed in vitro the transfection efficacy of the resulting lipopolyamines on HeLa and NIH3T3 cell lines (see Table 4).










Results in Table 4 show that the hydrophobicity of the lipid moiety has a crucial effect on in vitro gene transfer on any cell line tested. A decrease in chain length from 18 to 12 is associated with a decrease in transfection ability and increased cytotoxicity (data not shown). This study confirmed that RPR-120535 is a potential candidate for an extensive physicochemical characterization and in vivo gene transfer studies. Moreover, the chemical versatility of the amino acid linker in RPR-120535 prompted us to synthesize libraries with a variety of substituted linkers.

(5) Introduction of a Novel "Side Chain Entity" Element into the Linker Position of the Cationic Lipid: (a) A Library of Aliphatic, Aromatic, Cationic, or Targeting Moieties. We have introduced

amino acids instead of Gly in the linker position of RPR-120535, which were substituted by a variety of functions such as aliphatic or aromatic chains, novel cationic or targeting entities through their side chains (see Table 5).

The results in Table 5 show that the presence of a guanidinium group in addition to a single amino group in RPR-120533 results in a weak transfection activity both on Hela and NIH3T3 cells. On the other hand, introduction of positively charged Arg or Lys, instead of Gly in RPR-120535, to give RPR-120531 and RPR-127888, led to products with significant but slightly decreased transfection ability on both cell lines, as compared to RPR-120535. When negatively charged Glu is introduced in the same position in RPR-126097, a transfecting activity similar to that of RPR-120535 is observed. It should be pointed out that the introduction of a carboxylate side chain in RPR-126097 adds a negative charge and consequently diminishes the net cationic charges available for DNA binding. In contrast, introduction of a cationic amino side chain in RPR-127888 and RPR-120531, which increased the net positive charge of the vector, resulted in decreased transfection efficiency. Thus, it seems most likely that there is an optimal net charge for maximal transfection efficiency of cationic lipid, and that increasing the net charge of the cationic head might not always be beneficial. Additional substitution on the amino acid side chain provided products with significant transfection activity on both cell lines (see RPR-121650 with modified guanidine group, RPR-122759 with modified Lys, and finally RPR-130605 with a polyunsaturated aliphatic side chain). RPR-130605 contains an arachidonic fatty acid side chain which might be considered as a membrane-targeting or anchoring agent due to the facility of insertion of fatty acids in cellular phospholipid bilayers.

Table 5. Impact of the Introduction of a "Side Chain Entity" in the Linker Position on the Expression of Luciferase in Human Hela and Mouse Fibroblasts NIH3T3 Cells

N° RPR	Cationic Entity	Linker	Lipid	Hela cells [RLU]*	NIH3T3 cells [RLU]*
120533	-	Arg	N[(CH ₂) ₁₇ CH ₃] ₂	4.7 10 ³	8.7 10 ³
120531		Arg	N[(CH ₂) ₁₇ CH ₃] ₂	8.2 10 ⁶	1.1 10 ⁷
121650		Arg(Z ₂)	N[(CH ₂) ₁₇ CH ₃] ₂	1.2 10 ⁶	7.8 10 ⁷
126097		Glu	N[(CH ₂) ₁₇ CH ₃] ₂	1.5 10 ⁷	6.3 10 ⁷
127888		Lys	N[(CH ₂) ₁₇ CH ₃] ₂	7.0 10 ⁵	1.0 10 ⁷
122759			N[(CH ₂) ₁₇ CH ₃] ₂	1.4 10 ⁶	3.0 10 ⁷
130605			N[(CH ₂) ₁₇ CH ₃] ₂	4.6 10 ⁵	8.2 10 ⁶
120535		Gly	N[(CH ₂) ₁₇ CH ₃] ₂	1.0 10 ⁷	2.0 10 ⁸

* RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (see the Experimental Section).

On the basis of these results we have demonstrated that the introduction into cationic lipids of a linker bearing a side chain entity instead of glycine is indeed permitted for transfection *in vitro*. This possibility opens the field of specific targeting by introduction of peptides, glycosides, or other specific ligands.

(b) A Library of Molecular Probes for Vector Trafficking Studies. In view of investigating the intracellular fate of DNA/cationic lipid complexes, we have introduced two different molecular probes into the cationic lipids as the side chain entity. These products

contain either a biotine side chain in RPR-122761 or a rhodamine in RPR-121653, which are well-known tools for microscopy studies using either a streptavidine-labeled ligand or directly the fluorescence of rhodamine (see Table 6).

In previous reports on this domain, the fate of the cationic lipid/DNA complexes was followed by addition of an additive labeled lipid to the complexes,^{3,17-18} whereas we propose here the first directly labeled functional cationic lipids for such traffic studies. These labeled lipids were assayed on cell lines suitable for

Table 6. Impact of the Introduction of Molecular Probes as Side Chain Entities in the Linker Position on the Expression of Luciferase in Mouse Fibroblasts NIH3T3 and Monkey CV1 Cell Lines

N° RPR	Cationic Entity	Linker	Lipid	NIH3T3 cells [RLU] ^a	CV1 cells [RLU] ^a
120535		Gly	N[(CH ₂) ₁₇ CH ₃] ₂	2.6 10 ⁷	0.7 10 ⁴
122761			N[(CH ₂) ₁₇ CH ₃] ₂	5.4 10 ⁶	1.6 10 ⁵
121653			N[(CH ₂) ₁₇ CH ₃] ₂	1.2 10 ⁶	1.3 10 ⁵

^a RLU = luciferase activity in relative light units (RLU)/10 s for 10³ plated cells (see the Experimental Section).

Table 7. Cationic Lipid-Mediated Luciferase Reporter Gene Transfer into Lewis Lung Carcinoma Tumors

expt	μ g of DNA/tumor	cationic lipid		10 ⁶ [RLU/tumor] ^a mean \pm SE	n [*]
		no. RPR	nmol/ μ g of DNA		
1	10	126 097	6	1.38 \pm 0.38	6
	10	120 535	6	4.04 \pm 0.99	6
2	10	126 097	6	2.19 \pm 1.45	3
	10	130 605	6	0.66 \pm 0.43	3


^a RLU = luciferase activity in relative light units (10⁶ RLU = 30 pg luciferase).

microscopy studies (mouse NIH3T3 and monkey CV1 fibroblasts). Both products showed significant in vitro gene delivery activity on both cell types (see Table 6) as compared to RPR-120535, which allowed subsequent intracellular traffic studies.¹⁹

(6) In Vivo Transfection on the Lewis Lung Carcinoma Tumor Model. We have selected RPR-120535 (with a linear geometry of the polyamine head and an unsubstituted linker), RPR-126097 (with a linear geometry of the polyamine head and a polyunsaturated side chain entity on linker), and RPR-130605 (linear geometry of the polyamine head and an anionic side chain entity on linker) to study and compare their gene transfer ability in the Lewis lung carcinoma tumor model²⁰ (3LL) in vivo. This model is widely used for evaluation of antitumoral activity, as it induces distant metastasis and allows to work on syngenic immuno-competent mice.²¹ These tumors are developing rapidly and are highly necrotic. We injected cationic/DNA complexes directly into tumors grown subcutaneously.

Table 7 shows that the three products RPR-120535, 126097, and 130605 displayed significant transfection activity in 3LL tumor, whereas injection of naked DNA was unable to induce any luciferase activity above background (<10⁴ RLU/tumor; data not shown), thus suggesting their interest as potential candidates for preclinical development. The presence of a "membrane-anchoring entity" such as arachidonyl group on the

charge ratio +/-
0.08 0.15 0.3 0.7 1 1.3 3 6

**Figure 5.** Gel retardation of RPR120535/DNA complexes as a function of lipopolyamine to plasmid DNA charge ratio.

substituted linker in RPR-130605 did not enhance gene transfer in this in vivo model.

(7) Physicochemical Characterization of DNA/RPR-120535 Complexes. Taking RPR-120535 as a model compound, we performed a primary characterization of lipopolyamine complexes with DNA. In a first approach we performed gel retardation experiments (see Figure 5). Complexes whose amine/phosphate charge ratios (\pm) ranged from 0 to 0.7 exhibited free DNA migrating normally into the gel, and the gel wells were fluorescent. Therefore in this zone were present both free DNA and RPR-120535/DNA complexes accessible to the ethidium bromide. For RPR-120535/DNA complexes with a charge ratio over 0.7, all DNA was completely associated to RPR-120535 and, consequently, retarded on the gel.

Subsequently, fluorescence experiments were performed by exposing RPR-120535/DNA complexes to ethidium bromide, whose fluorescence increases upon intercalation between DNA base pairs. The fluorescence intensity of each sample is depicted in Figure 6. A large and very sharp decrease of the fluorescence intensity was observed for RPR-120535/DNA charge ratios ranging from 0 to 1. The fluorescence signal was constant and remained low for lipid/DNA complexes




Figure 6. Ethidium bromide fluorescence of RPR120535/DNA complexes as a function of cationic lipid to DNA charge ratio. *a.u. = arbitrary units.

whose charge ratios were over 1. Therefore, plasmid DNA is accessible to ethidium bromide for RPR-120535/DNA charge ratios ranging from 0 to 1 while over the latter ratio the plasmid DNA was inaccessible to ethidium bromide intercalation.

Results from gel electrophoresis retardation and ethidium bromide exclusion suggest that plasmid DNA is likely in a compacted state when complexed with RPR-120535. This compacted state is probably responsible for DNA protection against degradation in the presence of DNases we have observed (data not shown). Extensive physicochemical studies concerning the supramolecular structure and packaging of DNA/lipid complexes will be reported separately.²²

Conclusions

We have demonstrated that the use of solid-phase synthesis is a powerful tool for the easy and quick synthesis of a variety of geometrically differing polyamines as lipopolyamine cationic head. The feasibility of the method was demonstrated by the synthesis of a variety of unsymmetrically functionalized polyamines on a solid-phase support and their introduction into lipopolyamines. The SAR studies demonstrate the potential of several products in *in vitro* as well as in *in vivo* models. The most active products do not necessitate additives such as DOPE to obtain optimal activity. Although the presence of a guanidinium group and an amine as cationic entities do not afford considerable transfection activity to cationic lipids, the guanidinium groups as a complement to polyamines contributed to a gain in the transfection efficiency at low cationic lipid/DNA charge ratio (data not shown). Most lipopolyamines studied so far bear T-shaped cationic heads. Interestingly, we present here original linear shaped polyamines which display advantageous DNA-complexing property and transfection efficiency. These interesting properties might result from the increased steric flexibility of a less constrained polyamine linked to the lipidic moiety by one of its extremities, allowing a constructive interaction with polyanionic DNA. However, one must be careful in such SAR studies since *in vivo* data do not necessarily correlate with *in vitro* results.⁷ Advantages in terms of formulation and cytotoxicity of the leading product RPR-120535 were shown as compared to commercially available cationic lipids.

RPR-120531, RPR-120535, and RPR-130605 are currently being developed for preclinical studies, and RPR-121653 and RPR-122761 are being used as molecular probes to study the intracellular traffic of DNA/cationic lipid complexes.¹⁹ The demonstration that introduction of a novel side chain entity by substitution of the linker in the lipopolyamine is permitted opens the field of specific targeting. The synthesis of a novel series of lipopolyamines having specific tissue/cell-targeted side chain entities such as peptides, sugars, or steroids is currently underway.

Experimental Section

Materials and Methods. Triethylamine, diisopropylethylamine, and arachidonic acid were purchased from Aldrich-France and used without further purification, Boc-amino acids, 2-chlorotriethyl chloride resin, and BOP reagent were purchased from Neosystem, France. All solvents were analytically pure grade and were used without further purification.

Analytical and semipreparative HPLC were performed on a Merck-Hitachi gradient pump equipped with a AS-2000A autosampler, a L-6200A Intelligent pump, and a UV-vis detector L-4000 with tuneable wavelength set at 220 nm for analytical separations and 235 nm for semipreparative purifications. Preparative HPLC was performed on a Gilson gradient system equipped with two 305 intelligent pumps, a UV-vis Gilson 119 detector with double channel set at 220 and 254 nm, and a fraction collector Gilson 202.

Mobile phases were (A) H₂O (0.1% TFA) and (B) MeCN (0.08% TFA). Separation conditions are as follows: *Analytical*: column BU-300 aquapore Butyl 7m, 300A 300 × 4.6 mm from Perkin-Elmer, gradient H₂O/MeCN: 3 min [40/60], 3–20 min [0/100], 35 min [0/100]; flow, 1 mL/min, *I* = 220 nm. *Semipreparative*: biosil C18 HL 90-10 250-10 mm from Biorad, gradient H₂O/MeCN: 10 min [100/0], 10–45 min [0/100], 45–140 min [0/100]; flow, 4 mL/min, *I* = 220 nm. *Preparative*: column C4 Vydac-214 TP 1022 (10 mm) from Vydac, gradient H₂O/MeCN: 0–10 min [70/30], 10–80 min [0/100], 80–120 min [0/100]; flow, 18 mL/min, *I* = 220 and 254 nm. NMR and MS were carried out at the Analysis Department of Rhône Poulenc Rorer, Vitry sur Seine. ¹H NMR spectra were recorded on Bruker 300, 400, and 600 MHz spectrometers. Samples were dissolved in CDCl₃ or DMSO. Chemical shifts are in ppm relative to TMS internal standard. Mass spectra were carried out on a VG Autospec by LSIMS technique equipped with a cesium cannon, the matrix was a mixture of glycerol and thioglycerol or nitrobenzyl alcohol (FABMS), and a Perkin-Elmer Sciex API (III) MS. Yields of products [1–5] were calculated based on an initial loading of 0.6 mmol/g of solid support; the extent of this initial loading has a direct impact on the general yield. Thus, the yields vary depending on the quality and freshness of the starting chlorotriethyl chloride resin.

The presence of polyamines in the cationic lipids makes elementary analysis not adequate as a purity criteria. The polyamines are highly hygroscopic, and they can adopt a different salt degree. As prove of our findings, we have performed a complete analysis of the leading product RPR-120535 (annexed document) including MS, IR, and ¹H NMR recorded with an Avance DMX 600 Bruker (2D DQF COSY and HOHAHA methods, *t* = 80 ms) and ¹³C NMR (heteronuclear 2D techniques HMQC and HMBC with a delay of 50 ms in the reverse mode). Thus, we could unambiguously confirm the proposed structure, although the elementary analysis was not within the ±0.4% purity criteria (see the Experimental Section).

General Procedures. Method 1: Synthesis of Mono-functionalized Polyamines. (A) **Anchorage of the Acidic Function to the Polymeric Support.** Briefly, *O*-chlorotriethyl chloride resin (5 g, 1.2 mmol of Cl/g of resin from Nova) was placed in the solid-phase synthesis flask and 50 mL of CH₂-Cl₂ was added, followed by bromoacetic acid (for products 1–3) (1.05 g, 7 mmol) or acrylic acid for product 5 (0.5 g, 7 mmol)

and DIEA (0.95 mL, 7.5 mmol). The flask was placed into a motor flask shaker and was shaken for 2 h at room temperature. The solution was then filtered, and the resin beads were washed alternatively with CH_2Cl_2 and $^i\text{PrOH}$ (3×50 mL) and MeOH (2×50 mL) and dried on N_2 .

(B) Reaction of the Polyamine with the Bromoacetyl Resins. Molar excesses of 10-fold of polyamines were dissolved in 50 mL of DMF or CH_2Cl_2 , added to the flask, and agitated for 2 h. The solvent was filtered, and the resin was washed alternatively with CH_2Cl_2 and $^i\text{PrOH}$ (3×50 mL). Kaiser tests (cold and 110°C) are positive.

(C) Protection of the Amine Groups of the Functionalized Polyamine on the Solid Support. Di-*tert*-butyl dicarbonate (48 mmol) and DIEA (50 mmol) were dissolved in dichloromethane (50 mL) and added to the flask shaker; the reaction was left overnight at room temperature under shaking. The solvent was filtrated, and the resin was washed alternatively with CH_2Cl_2 and $^i\text{PrOH}$ (10×50 mL), MeOH (2×50 mL), and ether (2×50 mL) and dried on N_2 . The Kaiser test was negative.

(D) Cleavage of the Protected Polyamino Acids from the Resin. The resin was placed in a 250 mL round-bottomed flask equipped with a magnetic stirrer. A solution composed of 50 mL of CH_2Cl_2 and 25 mL of $\text{CF}_3\text{CH}_2\text{OH}$ was added and stirred for 2 h at room temperature. The solution was filtered and the resin washed with 100 mL of CH_2Cl_2 . The organic fractions were collected and evaporated. The crude products were purified by flash chromatography on SiO_2 with $\text{CHCl}_3/\text{MeOH}$ (9:1 or 8:2). The fractions containing the good products were identified by TLC and characterized by mass spectroscopy and NMR.

Method 2: Synthesis of Lipopolyamines. The protected carboxyl-functionalized polyamines **1–5** obtained by method 1 were reacted with amine components with BOP reagent. Briefly, to a stirred solution of the amino component (1 mmol) in MeCN or DMF were added BOP reagent (1.1 mmol), the acid component (1.1 mmol), and DIEA (3 mmol) at room temperature. After 15 min the pH was checked for basicity (in cases where the pH was lower than pH = 9, more DIEA was added) and the reaction mixture left at room temperature for 1 h. The reaction was followed by fluorescamine test. When the test was negative, the solvent was evaporated, and the crude product was dissolved in EtOAc (100 mL) and washed with KHSO_4 , NaHCO_3 , and saturated NaCl. The final Boc-protected products were deprotected using trifluoroacetic acid for 1 h and purified by HPLC. Z or ClZ protecting groups were cleaved as previously described.²³

BocNH(CH₂)₃NBoc(CH₂)₄NBoc(CH₂)₃NBocCH₂CO₂H (1). Product **1** was synthesized using method 1: yield 40%; TLC R_f = 0.9 ($\text{CHCl}_3/\text{MeOH}$, 8:2); HPLC t_R = 4.22 min ($\text{H}_2\text{O}/\text{MeCN}$: 3 min [40/60], 3–20 min [0/100], 35 min [0/100]). ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$ with some drops of $\text{CD}_3\text{COOD}-d_4$, δ in ppm) 1.40 (4 s, 36H, $\text{C}(\text{CH}_3)_3$), 1.46 (mt, 4H, CH_2CH_2 central butylene), 1.64 and 1.74 (2 mts, 2H each, CH_2 central propylene), 2.96 (t, J = 7 Hz, 2H, CH_2NCOO), 3.15 (mt, 8H, CH_2NCH_2), 3.23 (t, J = 7.5 Hz, 2H, CH_2NCOO), 3.83 (s, 2H, $\text{OCONCH}_2\text{COO}$); MH^+ 661.

BocNH(CH₂)₃NBoc(CH₂)₄N[(CH₂)₃NHBoc]CH₂CO₂H (2). During the synthesis of product **1**, product **2** was isolated after SiO_2 purification with a yield of 20%. TLC R_f = 0.5 ($\text{CHCl}_3/\text{MeOH}$, 8:2); ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, δ in ppm) 1.30–1.60 (mt, 4H, $(\text{CH}_2)_2$ centrals butylene), 1.40 (s, 27H, $\text{C}(\text{CH}_3)_3$), 1.56 (mt, 4H, CH_2 propylenes), 2.68 and 3.11 (respectively t broad and t, J = 7 Hz, 4H each, NCH_2 butylene and NCH_2 propylenes), 2.90 and 2.96 (2 q, J = 7 Hz, 2H each, BocNHCH_2 propylenes), 3.18 (s, 2H, NCH_2COO); MH^+ 561.

{BocNH(CH₂)₃}₂N(CH₂)₄N{(CH₂)₃NHBoc}(CH₂)₃NBocCH₂CO₂H (3). Product **3** was synthesized using method 1: yield 35%; TLC R_f = 0.2 ($\text{CHCl}_3/\text{MeOH}$, 8:2); ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$ with some drops of $\text{CD}_3\text{COOD}-d_4$, temperature of 433 K, δ in ppm) 1.42 (s, 36H, $\text{C}(\text{CH}_3)_3$), 1.56 (mt, 4H, CH_2CH_2 central butylene), from 1.65 to 1.85 (mt, 8H, CH_2 central propylenes), 2.76 (mt, 12H, $\text{CH}_2\text{N}(\text{CH}_2)_2$), 3.06 (t, J =

6.5 Hz, 6H, OCONCH_2), 3.29 (mt, 2H, NCH_2), 3.86 (s, 2H, $\text{OCONCH}_2\text{COO}$); MH^+ 775.

{BocNH(CH₂)₃}₂N(CH₂)₂NBocCH₂CO₂H (4). Product **4** was synthesized using method 1: yield 29%; TLC R_f = 0.55 ($\text{CHCl}_3/\text{MeOH}$, 8:2); ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$ temperature of 393 K, δ in ppm) 1.44 (s, 27H, $\text{C}(\text{CH}_3)_3$), 2.58 (t, J = 6.5 Hz, 4H, CH_2NCH_2), 2.66 (t, J = 7 Hz, 2H, NCH_2), 3.04 (q, J = 6.5 Hz, 4H, OCONCH_2), 3.28 (t, J = 7 Hz, 2H, OCONCH_2), 3.76 (s, 2H, $\text{OCONCH}_2\text{COO}$), 6.06 (mf, 2H, CONH), MH^+ 505.

BocNH(CH₂)₃NBoc(CH₂)₄NBoc(CH₂)₃NBocCH₂CH₂CO₂H (5). Product **5** was synthesized using method 1: yield 40%; TLC R_f = 0.63 ($\text{CHCl}_3/\text{MeOH}$, 8:2); ^1H NMR (300 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, δ in ppm) 1.43 (m, 40H, $\text{C}(\text{CH}_3)_3$ and $(\text{CH}_2)_2$ of butyl), from 1.55 to 1.80 (m, 4H, CH_2 of propyl), 2.45 (t, J = 7 Hz, 2H, CH_2COO), 2.93 (q, J = 7 Hz, 2H, NCH_2), from 3.05 to 3.50 (m, 12H, NCH_2), 6.82 (bb, 1H, NHCO); MH^+ 675.

RPR-120525. Product **3** was coupled with glycyldioctadecylamide using method 2 and purified by HPLC using semipreparative method: t_R = 38.72 min; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, T = 386 K, δ in ppm) 0.90 (t, J = 7 Hz, 6H, CH_3), 1.30 (mt, 60H, CH_2 central/lipid chains), 1.55 (mt, 4H, 1 CH_2 from every lipid chain), 1.65 (mt, 4H, CH_2CH_2 central/butyl), 1.97 (mt, 8H, CH_2 central/propyls); from 2.80 to 3.05–3.06 and 3.28 (mt, 2 t, J = 7.5 Hz, 18H – 2H and 4H, NCH_2), 3.80 (s, 2H, NCH_2CON), 4.03 (d, J = 5.5 Hz, 2H, CONCH_2CON), from 6.00 to 9.00 (mt, NH_2 and NH), 8.27 (mt, 1H, CONH); MH^+ 935.

RPR-120526. Product **3** was coupled with dioctadecylamine using method 2 and purified by HPLC using semipreparative method: t_R = 38 min; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, T = 386 K, δ in ppm) 0.88 (t, J = 7 Hz, 6H, CH_3), 1.29 (mt, 60H, CH_2 central/lipid chains), 1.52 (mt, 4H, 1 CH_2 from each lipid chain), 1.68 (mt, 4H, CH_2CH_2 central/butyl), from 1.90 to 2.10 (mt, 8H, CH_2 central/propyl), 2.90 from 2.95 to 3.15–3.18 and 3.15 (t, mt and 2 t broad, J = 7.5 Hz, 24H, NCH_2), 4.02 (s, 2H, NCH_2CON); MH^+ 878.

RPR-120527. Product **4** was coupled with dioctadecylamine using method 2 and purified by HPLC using semipreparative method: t_R = 100.1 min; MH^+ 708.

RPR-120528. Product **4** was coupled with glycyldioctadecylamide using method 2 and purified by HPLC using semipreparative method: t_R = 122 min; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, T = 386 K, δ in ppm) 0.87 (t, J = 7 Hz, 6H, CH_3), from 1.15 to 1.35 (mt, 60H, CH_2 central/lipid chains), 1.45 and 1.55 (2 mts, 2H each, 1 CH_2 from each lipid chain), 2.64 (t, J = 5.5 Hz, 4H, CH_2NCH_2), 2.75 (t, J = 6 Hz, 2H, NCH_2), 2.95 (t, J = 5.5 Hz, 4H, NCH_2), 3.08 (t, J = 6 Hz, 2H, NCH_2), 3.25 (mt, 4H, NCH_2 lipid chains), 3.88 (s, 2H, NCH_2CON), 4.06 (d, J = 5 Hz, 2H, CONCH_2CON), 7.75 (mf broad/residual, NH), 8.68 (t residual, J = 5 Hz, CONH); MH^+ 765.

RPR-120531. Product **1** was coupled with Arg(Z_2)dioctadecylamide using method 2. The final deprotected product was purified using HPLC preparative method: t_R = 13.83 min (analytical method); ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, T = 386 K, δ in ppm) 0.90 (t, J = 7 Hz, 6H, CH_3), 1.28 (mt, 60H, CH_2 lipid chains), from 1.40 to 1.80 (mt, 12H, CH_2), 1.93 (mt, 4H, CH_2 central/propyls), from 2.80 to 3.10 (mt, 16H, NCH_2 and NCH_2 lipid chains), 3.42 (mt, 2H, CH_2N amide), 3.77 (mt, 2H, NCH_2CON), 4.67 (mt, 1H, NCHCON), from 6.80 to 7.50 (mf broad, 2H, NH_2), 7.78–7.92–8.80 and 9.03 (mt and 3mfs, 1H – 2H – 4H and 1H, CONH – NH and NH_2); MH^+ 920.

RPR-120534. Product **1** was coupled to dioctadecylamine using method 2 and purified using HPLC semipreparative method: t_R = 15.2 min (analytical method); ^1H NMR (400 MHz, mixture of $^2/3\text{CF}_3\text{COOD}$ and $^1/3\text{CD}_3\text{COOD}-d_4$, δ in ppm) 0.78 (t, J = 7 Hz, 6H, CH_3), 1.20 (mt, 60H, CH_2 central/lipid chains), 1.52 (mt, 4H, 1 CH_2 from each lipid chain), 1.80 (mt, 4H, CH_2CH_2 central/butyl), 2.23 and 2.32 (2 mts, 2H each, CH_2 central/propyls), from 3.10 to 3.40 (3 mts, 16H, NCH_2), 4.15 (s, 2H, NCH_2CON); MH^+ 764.

RPR-120535. Product **1** was coupled to glycyldioctadecylamide using method 2 and purified by HPLC using preparative method: t_R = 15.35 min (analytical method); ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}-d_6$, T = 300 K, δ in ppm) 0.83 (t, J = 7 Hz,

6H, CH₃), 1.23 (mt, 60H, CH₂ central/lipid chains), 1.43 and 1.53 (2 mts, 2H each, 1 CH₂ from each lipid chain), 1.63 (mt, 4H, CH₂CH₂ central/butyl), 1.96 (mt, 4H, CH₂ central/propyls), 2.93–3.00 and 3.22 (3 mts, 16H, NCH₂), 3.83 (s, 2H, NCH₂-CON), 4.03 (s, 2H, CONCH₂CON); MH⁺ 821. Anal. (C₅₀-H₁₀₄N₆O₂, acetate salt) C, calcd 65.6, found 64.1; H, calcd 11.4, found 12.05; N, calcd 7.9, found 8.16.

RPR-121650. The lipid is synthesized as RPR-120531, but Z groups were not cleaved. The product is purified by HPLC using the preparative method: *t_R* = 17.75 min (analytical method); ¹H NMR (400 MHz, (CD₃)₂SO, δ in ppm) 0.87 (t, *J* = 7 Hz, 6H, CH₃), 1.25 (mt, 60H, CH₂ central/lipid chains), 1.40 and 1.57 (2 mts, 2H each, 1 CH₂ each lipid chain), 1.65 (mt, 8H, CH₂CH₂ central/butyl), 1.95 (mt, 4H, CH₂ central/propyls), from 2.85 to 3.05 (mt, 14H, NCH₂), 3.23 (t, *J* = 7.5 Hz, 2H, NCH₂), 3.75 (s, 2H, NCH₂CON), 3.85 and 3.95 (2 mts, 1H each, CH₂NC), 4.67 (mt, 1H, CONCHCON), 5.07 and 5.25 (AB and s, *J* = 13.5 Hz, 2H each, NCOOCH₂Ar), from 7.25 to 7.45 (mt, 10H, H aromatics), 7.95–8.85–9.00 and 9.20 (4 mfs, H exchangeables); MH⁺ 1188.

RPR-122759, RPR-121653, and RPR-122761. Product **1** was coupled to Lys(CIZ)dioctadecylamide using method 2 without deprotection. The product was used for the synthesis of RPR-122759, RPR-121653, and RPR-122761. **RPR-122759** was obtained after cleavage using TFA and purification by HPLC using preparative method: *t_R* = 16.79 min (analytical method); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 373K, δ in ppm) 0.91 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.31 (mt, 60H, (CH₂)₁₅ central/lipid chains), from 1.30 to 1.75 (mt, 10H, 1 CH₂ from each lipid chain, (CH₂)₃ central Lys), 1.72 (mt, 4H, (CH₂)₂ central/butyl), 1.95 (mt, 4H, CH₂ propyls), 2.98–3.06 and from 2.90 to 3.50 (2 mts and mf, 18H overall, NCH₂ Lys – NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains), 3.59 (s, 2H, NCH₂CON), 4.75 (q, *J* = 7 Hz, 1H, CONCHCON Lys), 5.16 (s, 2H, COOCH₂Ar), 6.85 (mf, 1H, OCONH), from 7.35 to 7.55 (mt, 5H, H aromatics), 8.15 (mf, 1H, CONH Lys); MH⁺ 1060.

RPR121653 was obtained after deprotection of the CIZ group as previously described²³ and reaction of the partially deprotected intermediate (77 mg, 60 mmol) with tetramethyl rhodamine isothiocyanate (30 mg, 68 mmol) in 3 mL of MeOH and in the presence of DIEA (64 mL) overnight. The solution is evaporated in vacuo, and the obtained red colored solid is treated with 4 mL of TFA during 1 h, the TFA is evaporated, and the product is purified by HPLC using semipreparative method: *t_R* = 61.55 min (semipreparative method); MH⁺ 1335.

RPR-122761 was obtained after deprotection of the CIZ group as previously described²³ and coupling of the partially deprotected intermediate with biotine in DMF using method 2. The product was purified by HPLC using semipreparative method: *t_R* = 13.12 min (analytical method); MH⁺ 1118.

RPR-122766. The lipid was synthesized as RPR-120535 but using glycylditetradecylamide instead of glycyldioctadecylamide. The product was purified by HPLC using semipreparative method: *t_R* = 9.54 min (analytical method); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 393 K, δ in ppm) 0.90 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.31 (mt, 44H, (CH₂)₁₁ central/lipid chains), 1.58 (mt, 4H, 1 CH₂ from each lipid chain), 1.76 (mt, 4H, (CH₂)₂ central/butyl), 2.00 (mt, 4H, CH₂ central/propyls), 2.98 and 3.08 (mt and t, *J* = 7 Hz, 12H, NCH₂ butyl and NCH₂ propyls), 3.30 (t, *J* = 7 Hz, 4H, NCH₂ lipid chains), 3.65 (s, 2H, NCH₂CON), 4.06 (d, *J* = 4 Hz, 2H, CONCH₂CON Gly), 8.10 (mf, 1H, CONH Gly); MH⁺ 709.

RPR-122767. The lipid was synthesized as RPR-120535 but using glycyldidodecylamide instead of glycyldioctadecylamide. The product is purified by HPLC using semipreparative method: *t_R* = 9.92 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 403K, δ in ppm) 0.93 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.33 (mt, 36H, (CH₂)₉ central/lipid chains), 1.58 (mt, 4H, 1 CH₂ from each lipid chain), 1.75 (mt, 4H, (CH₂)₂ central/butyl), 1.95 and 2.00 (2 mts, 2H each, CH₂ central/propyls); 2.98 and 3.00 (2 mts, 12H, NCH₂ butyl and NCH₂ propyls), 3.30 (t, *J* = 7 Hz, 4H, NCH₂ lipid chains), 3.58 (s, 2H, NCH₂CON), 4.05 (s, 2H, CONCH₂CON Gly); MH⁺ 653.

RPR-122774. The lipid was synthesized as RPR-120535 but using glycylditridecyldecylamide instead of glycyldioctadecylamide. The product is purified by HPLC using the semipreparative method: *t_R* = 10.64 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 393 K, δ in ppm) 0.91 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.33 (mt, 40H, (CH₂)₁₀ central/lipid chains), 1.58 (mts, 4H, 1 CH₂ from each lipid chain), 1.75 (mt, 4H, (CH₂)₂ central/butyl), 2.00 (mt, 4H, CH₂ central/propyls), 2.98 and 3.08 (2 t, *J* = 7 Hz, 12H, NCH₂ butyl and NCH₂ propyls), 3.32 (t, *J* = 7 Hz, 4H, NCH₂ lipid chains), 3.65 (s, 2H, NCH₂CON), 4.06 (d, *J* = 4 Hz, 2H, CONCH₂CON Gly), 8.60 (s large, 1H, CONH Gly); MH⁺ 681.

RPR-122786. In a 500 mL round-bottomed flask are poured spermine (1.8 g, 9 mmol), methanol (60 mL), and NaCNBH₃ (0.138 g, 2.3 mmol). The solution is vigorously stirred, and 35.5 mL of a solution composed of 5.5 mL of succinic semialdehyde 15% and 30 mL of methanol is added dropwise during 2 h. The reaction mixture is left for additional 2 h and the amines protected with di-*tert*-butyl dicarbonate as usual. The solution is evaporated and the crude product redissolved in ethyl acetate (100 mL) and extracted with saturated NaHCO₃ (3 × 100 mL). The aqueous phase is washed with ether (3 × 50 mL) and 0/5 M KHSO₄ is added until pH = 3. Turbidity is observed, and the aqueous phase is extracted with ethyl acetate (3 × 100 mL). The organic layer is dried on MgSO₄ and evaporated in vacuo. The product, BocNH(CH₂)₃NBoc(CH₂)₄NBoc(CH₂)₃NBoc(CH₂)₃CO₂H, was coupled with dioctadecylamine using method 2. The obtained product is purified by HPLC using semipreparative conditions: *t_R* = 15.04 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 383 K, δ in ppm) 0.85 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.22 (mt, 60H, (CH₂)₁₅ central lipid chains), 1.48 (mf, 4H, 1 CH₂ from each lipid chain), 1.72 (mt, 4H, (CH₂)₂ central/butyl), 1.88 (mt, 2H, CH₂ central NH-pentanoyl), 1.99 (mt, 4H, CH₂ propyls), 2.42 (t, *J* = 7 Hz, 2H: COCH₂ from NH-pentanoyl), 2.96–3.03 and 3.22 (3 mts, 18H, NCH₂ from NH-pentanoyl – NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains); MH⁺ 792.

RPR-126096. The lipid was synthesized as RPR-120535 but using product **2** instead of product **1**. The product is purified by HPLC using preparative method: *t_R* = 13.6 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆ with some drops CD₃COOD-*d*₄, δ in ppm) 0.87 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.28 (mt, 60H, (CH₂)₁₅ central lipid chains), 1.46 and 1.54 (2 mts, 2H each, 1 CH₂ from each lipid chain), 1.63 (mt, 4H, (CH₂)₂ central/butyl), 1.91 (mt, 4H, CH₂ propyls), from 2.85 to 3.15 (mt, 12H, NCH₂ butyl and NCH₂ propyls), 3.24 (mt, 4H, NCH₂ lipid chains), 3.76 (mf, 2H, NCH₂CON), 4.05 (s broad, 2H, CONCH₂CON from Gly); MH⁺ 821.

RPR-126097. The lipid was synthesized as RPR-120535 but using Glu(Bz)dioctadecylamide instead of Gly-dioctadecylamide. The Bz group was cleaved as previously described.²³ The product is purified by HPLC using preparative method: *t_R* = 14.64 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 383 K, δ in ppm) 0.90 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.30 (mt, 60H, (CH₂)₁₅ central lipid chains), 1.56 (mf, 4H, 1 CH₂ from each lipid chain), from 1.60 to 2.00 (mt, 2H, CH₂ central Glu), 1.73 (mt, 4H, (CH₂)₂ central/butyl), 1.98 (mt, 4H, CH₂ propyls), 2.32 (t, *J* = 7 Hz, 2H, COCH₂Glu), 3.00–3.06 and 3.45 (t and 2 mts, *J* = 7 Hz, 16H, NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains), 3.65 (s broad, 2H, NCH₂CON), 4.85 (mt, 1H, CONCHCON Glu), 8.19 (s broad, 1H, CONH Glu); MH⁺ 893.

RPR-127888. Product RPR-122759 is deprotected as previously reported to give RPR-127888. The product is purified by HPLC using semipreparative method: *t_R* = 11.76 min (analytical); ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆, 393 K, δ in ppm) 0.91 (t, *J* = 7 Hz, 6H, CH₃ lipid chains), 1.31 (mt, 60H, (CH₂)₁₅ central/lipid chains), from 1.35 to 1.75 (mt, 10H, 1 CH₂ from each lipid chain, (CH₂)₃ central/Lys), 1.75 (mt, 4H, (CH₂)₂ central/butyl), 2.00 (mt, 4H, CH₂ propyls), 2.82–2.98–3.06 and from 3.10 to 3.50 (2 t – mt and 2mfs, *J* = 7 Hz, 18H, NCH₂ Lys – NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains),

3.62 (s, 2H, NCH₂CON), 4.73 (q, $J = 7$ Hz, 1H, CONCHCON Lys), 8.18 (d, $J = 7$ Hz, 1H, CONH Lys); MH⁺ 892.

RPR-128506. The lipid was synthesized as RPR-120535 but using 6-(aminocaproyl)dioctadecylamide instead of glycyldioctadecylamine. The product was purified by HPLC using semipreparative method: $t_R = 13.94$ min (analytical); ¹H NMR (300 MHz, (CD₃)₂SO-*d*₆, δ in ppm) 0.87 (t, $J = 7$ Hz, 6H, CH₃ lipid chains), 1.28 (mt, 60H, (CH₂)₁₅ central/lipid chains), 1.48 (mt, 10H, 1 CH₂ from each lipid chain and (CH₂)₃ central/aminohexanoyl), 1.65 (mt, 4H, (CH₂)₂ central/butyl), 1.95 (mt, 4H, CH₂ propyls), 2.27 (t, $J = 7$ Hz, 2H, COCH₂ aminohexanoyl), from 2.85 to 3.30 (mts, 18H, NCH₂ aminohexanoyl – NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains), 3.70 (s broad, 2H, NCH₂CON), from 7.90 to 9.10 (mfs exchangeables); MH⁺ 877.

RPR-130605. The lipid was synthesized as RPR-121653 but using arachidonic acid instead of rhodamine–isothiocyanate, which was coupled to the intermediate semiprotected product using method 2. The product was purified by HPLC using the semipreparative method: $t_R = 20.67$ min; ¹H NMR (400 MHz, (CD₃)₂SO-*d*₆ some drops of CD₃COOD-*d*₄, 393 K, δ in ppm) 0.90 (t, $J = 7$ Hz, 6H, CH₃ lipid chains), 0.91 (t, $J = 7$ Hz, 3H, arachidonyl), 1.31 (mt, 60H, (CH₂)₁₅ central/lipid chains), from 1.35 to 1.75 (mt, 18H, 1 CH₂ from each lipid – (CH₂)₃ central and CH₂ central/arachidonyl and (CH₂)₃ central/Lys), 1.75 (mt, 4H, (CH₂)₂ central/butyl), 2.02 (mt, 4H, CH₂ propyls), 2.10 (mt, 6H, COCH₂ and two =CCH₂ from arachidonyl), 2.80–2.97–3.06 and from 3.10 to 3.50 (mt – t – mt and 2 mfs, $J = 7$ Hz, 24H, =CCH₂C= from arachidonyl – NCH₂ Lys – NCH₂ butyl – NCH₂ propyls and NCH₂ lipid chains), 3.62 (s, 2H, NCH₂CON), 4.73 (dd, $J = 8$ and 5 Hz, 1H, CONCHCON Lys), 5.38 (mt, 8H, CH=CH from arachidonyl); MH⁺ 1177.

In Vitro Transfections. 5×10^4 cells were plated in 24-well plates in Dubelcco Modified Eagle Medium (DMEM) for NIH3T3 and Hela cells and in Minimum Essential Medium (MEM) for CV1 cells at 37 °C in a humidified atmosphere containing 5% CO₂ so that the growth was exponential. Cells were transfected after 24 h of culture at 50/70% confluency. Immediately prior to transfection, cells were washed twice with 0.5 mL of serum free medium and then supplemented with 0.5 mL of serum free medium. Plasmid DNA containing the luciferase gene under the dependency of the cytomegalovirus (CMV) immediate early promoter purified according to standard procedure was mixed with a variable quantity of cationic lipid in 75 mM NaCl final concentration. The stock solution of cationic lipid (5 mM) was in aqueous solution. Four ratios of cationic lipid per DNA were studied, varying from 2 to 12 nmol of cationic lipid/mg of DNA. For each condition a triplicate determination was performed (1 mg of plasmid DNA/well). Extemporaneous mixing of DNA with cationic lipids was added dropwise to the cells. After 2 h of transfection, fetal calf serum was added (to a 10% final concentration). The cells were then incubated at 37 °C for an additional period of 44 h up to the evaluation of the efficiency of gene transduction.

For each cationic lipid, we have reported in the tables the luciferase activity observed at the optimal cationic lipid/DNA transfection ratio (generally 6 nmol of cationic lipid/mg of DNA).

In Vivo Gene Transfer. Lewis lung carcinoma tumors were passaged as explant from mouse to mouse. Typically, tumor fragments were inoculated subcutaneously into the flank of adult C57/BL6 mice. Tumors were injected with the plasmid-containing solution one week after inoculation, when the tumors reached a size around 100 mm³. Plasmid used was pXL 2621 derived from pGL2 control vector (Promega), in which the SV40 promoter has been replaced by the MluI/HindIII fragment of the CMV promoter extracted from pCDNA3 (in vitro). Briefly, plasmid was dissolved in a NaCl 150 mM, D-glucose 5%, Mes pH 6.2, 5 mM solution, to a final concentration of 0.1 mg/mL. Lipopolyamines were prepared as a 20 mM stock solution in ethanol, and the required amount of this solution was added to the plasmid-containing preparation. After at least 30 min of incubation at room temperature, 100

mL of this solution was injected directly into the tumors using a Hamilton syringe. Evaluation of luciferase activity was assessed in tumor homogenates 48 h after DNA injection.

Luciferase Assay for in Vitro and in Vivo Assays. Luciferase activity (Promega assay system) was monitored using a Berthold luminometer (10 s monitoring, 10⁶ relative light units (RLU) equivalent to 40 pg of luciferase). Tumor or cell samples were homogenized in Promega cell lysis buffer and, after centrifugation, 10 mL of supernatant was mixed with 50 mL of luciferase assay substrate (Promega). Protein was determined using Pierce assay system.

Physicochemical Characterization. Agarose Gel Electrophoresis. RPR120535/DNA samples containing 1 mg of DNA were loaded on a 0.8% agarose gel.

Fluorescence Studies. Fluorescence measurements were carried out on a Perkin-Elmer LS50 B spectrofluorophotometer, with slits of excitation and emission of 5 nm. Ethidium bromide was added to solutions containing complexes prepared at 10 mg of DNA/mL followed by the addition of ethidium bromide to a final concentration of 5 mM. All sample readings were recorded using an excitation wavelength of 260 nm and emission wavelength of 590 nm, and values were expressed as arbitrary fluorescence units. Measurements were conducted in a medium containing 150 mM NaCl.

Abbreviations: Boc, *tert*-butoxycarbonyl; BOP, (benzotriazolyl)tris(dimethylamino)phosphonium hexafluorophosphate; DC-Chol, 3 β -[*N*-(*N,N*-dimethylamino)ethyl]carbamoyle cholesterol; DDAB, dimethyldioctadecylammonium bromide; DIEA, diisopropylethylamine; DLRIE, (\pm)-*N*-(3-aminopropyl)-*N,N*-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide; DMRIE, 1,2-dimyrystoyloxypropyl-3-dimethylhydroxyethylammonium bromide; DNA, deoxyribonucleic acid; DOGS, dioctadecylamine–glycine–spermine; DOPE, dioleoylphosphatidylethanolamine; DOPSA, 2,3-dioleoyloxy-*N*-(2-(spermincarboxamido)ethyl)-*N,N*-dimethyl-1-propanaminium trifluoroacetate; LARLU, luciferase activity in relative light units; Z, benzyloxycarbonyl.

Acknowledgment. This work was supported by the CNRS and Rhône-Poulenc Rorer and a grant from La Ligue Nationale contre le Cancer. The project was done as part of the Bioavenir program with the participation of the French Ministries of Research and Industry. We thank Dr. Marc Vuilhorgne, Serge Sable, Silvie Gourhand, Marie-Claude Lavergne, and Martine Danzer from the Structural Analysis Department of Rhône-Poulenc Rorer for NMR, MS, and elemental analyses.

References

- (1) (a) Bishop, J. M. The Molecular Genetics of Cancer. *Science* **1987**, 235, 305–311. (b) Yang, Y.; Nunes, F. A.; Berencsi, K.; Furth, E. E.; Gonczol, E. and Wilson, J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, 91, 4407–4411.
- (2) (a) Felgner, P. L.; Rhodes, G. Gene Therapeutics. *Nature* **1991**, 349, 351–352. (b) Wheeler, C. J.; Felgner, P. L.; Tsai, Y. J.; Marshal, J.; Sukhu, L.; Doh, S. G.; Hartikka, J.; Nietupski, J.; Manthorpe, M.; Nichols, M.; Plewe, M.; Liang, X.; Norman, J.; Smith, A. and Cheng, S. H. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, 93, 11454–11459.
- (3) Felgner, P. L.; Gadek, T. G.; Holm, M.; Roman, R.; Chan, H. W.; Wenz, M.; Northrop, J. P.; Ringold, G. M.; Danielsen, M. Lipofection: A highly Efficient, Lipid-Mediated DNA-Transfection Procedure. *Proc. Natl. Acad. Sci. U.S.A.* **1987**, 84, 7413–7417.
- (4) Gao, X.; Huang, L. A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells. *Biochem. Biophys. Res. Commun.* **1991**, 179, 280–285.
- (5) Behr, J. P.; Demeneix, B.; Loeffler, J. P.; Perez-Mutul, J. Efficient Gene Transfer into Mammalian Primary Endocrine Cells with Lipopolyamine-Coated DNA. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, 86, 6982–6986.
- (6) Hawley-Nelson, P.; Ciccarone, V.; Gebeyehu, G.; Jesse, J.; Felgner, P. L. Lipofectamine Reagent: A new Higher Efficiency Polycationic Liposome Transfection Reagent. *Focus* **1993**, 15, 73–79.

- (7) Lee, E. R.; Marshall, J.; Siegel, C. S.; Jiang, C.; Yew, N. S.; Nichols, M. R.; Nietupsky, J. B.; Ziegler, R. J.; Lane, M. B.; Wang, K. X.; Wan, N. C.; Scheule, R. K.; Harris, D. J.; Smith, A. E.; Cheng, S. H. Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung. *Hum. Gene Ther.* **1996**, *7*, 1701–1717.
- (8) Felgner, J. H.; Kumar, R.; Sridhar, C. N.; Wheeler, C. J.; Tsai, Y. J.; Border, R.; Ramsey, P.; Martin, M.; Felgner, P. L. Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations. *J. Biol. Chem.* **1994**, *269*, 2550–2561.
- (9) Lasic, D. D. and Templeton, N. S. Liposomes in Gene Therapy. *Adv. Drug Delivery Rev.* **1996**, *20*, 221–266.
- (10) (a) Ruysschaert, J. M.; El Ouahabi, A.; Willeaume, V.; Huez, G.; Fuks, R.; Vandenbranden, M.; Di Stefano, P. A Novel Cationic Amphiphile for Transfection of Mammalian Cells. *Biochem. Biophys. Res. Commun.* **1994**, *203*, 1622–1628. (b) El Ouahabi, A.; Pector, V.; Fuks, R.; Vandenbranden, M. and Ruysschaert, J. M. Double Long-Chain Amidine Liposome-Mediated Self-Replicating RNA Transfection. *Acta Clin. Belg.* **1996**, *51*–3, 194.
- (11) (a) Lewis, J. L.; Lin, K.-Y.; Kothavale, A.; Flanagan, W. M.; Mateucci, M. D.; DePrince, R. B.; Mook, R. A., Jr.; Hendren, R. W.; Wagner, R. W. A Serum-Resistant Cytofectin for Cellular Delivery of Antisense Oligodeoxynucleotides and Plasmid DNA. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 3176–3181. (b) Vigneron, J. P.; Oudrhiri, N.; Fauquet, M.; Vergely, L.; Bradley, J. C.; Bassville, M.; Lehn, P.; Lehn, J. M. Guanidinium-Cholesterol Cationic Lipids: Efficient vectors for the Transfection of Eukaryotic Cells. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 9682–9686.
- (12) Byk, G.; Dubertret, C.; Schwartz, B.; Scherman, D. Nouveaux Agents de Transfection et Leur Applications Pharmaceutiques. French Patent Application FR9601774, 1995; International Patent Application PCT/FR96/01774, International Publication WO 9718185.
- (13) (a) Ganem, B. New Chemistry of Naturally Occurring Polyamines. *Acc. Chem. Res.* **1982**, *15*, 290–298. (b) Bergeron, R. J. Methods for the Selective Modification of Spermidine and its Homologs. *Acc. Chem. Res.* **1986**, *19*, 105–113. (c) Edwards, M. L.; Stemerick, D. M.; Kline, S. J. Stereospecific Synthesis of Secondary Amines by The Mitsunobu Reaction. *Tetrahedron Lett.* **1990**, *31*, 3417. (d) Blagbrough, I. S.; Moya, E.; Walford, S. P. Practical, Convergent Total Synthesis of Polyamines Amide Spider Toxin NSTX-3. *Tetrahedron Lett.* **1996**, *37*, 551–554. (e) Goulaouic-Dubois, C.; Guggisberg, A.; Hesse, M. Synthesis and Selective Deprotection of the Penta-N-Protected Polyamine 1,16-Diamino-4,8,13-triazahexadecane. *Tetrahedron* **1995**, *51*, 12573–12582.
- (14) Merrifield, R. B. Solid Phase Peptide Synthesis I. The Synthesis of a Tetrapeptide. *J. Am. Chem. Soc.* **1963**, *85*, 2149.
- (15) Byk, G.; Frederic, M.; Scherman, D. One Pot Synthesis of Unsymmetrically Functionalized Polyamines by a Solid Phase Strategy Starting from Their Symmetrical Polyamine-Counterparts. *Tetrahedron Lett.* **1997**, *38*, 3219–3222.
- (16) Castro, B.; Dormoy, J. R.; Dourtglou, B.; Evin, G.; Selve, C.; Ziegler, J. C. Peptide Coupling Reagents VI. A Novel, Cheaper Preparation of Benzotriazolyltris(dimethylamino) phosphonium Hexafluorophosphate (BOP Reagent). *Synthesis* **1976**, 751–752.
- (17) Vitiello, L.; Chonn, A.; Wasserman, J. D.; Duff, C.; Worton, R. G. Condensation of Plasmid DNA with Polylysine Improves Liposome-Mediated Gene Transfer into Established and Primary Muscle Cells. *Gene Ther.* **1996**, *3*, 396–404.
- (18) Wrobel, I.; Collins, D. Fusion of Cationic Liposomes with Mammalian Cells Occurs After Endocytosis. *Biochim. Biophys. Acta* **1995**, *1235*, 296–304.
- (19) Escriou, V.; Ciolina, C.; Lacroix, F.; Byk, G.; Scherman, D.; Wils, P. Cationic Lipid-Mediated Gene Transfer: Effect of Serum on Cellular Uptake and Intracellular Fate of Lipopolyamine/DNA Complexes. *Biochim. Biophys. Acta* **1997**, in press.
- (20) Mayo, J. C. Biologic Characterization of the Subcutaneously Implanted Lewis Lung Tumor. *Cancer Chemother. Rep. Part 2* **1972**, *3*, 325–330.
- (21) Lavelle, F.; Bissery, M.-C.; André, S.; Roquet, F.; Riou, J.-F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. *Sem. Oncol.* **1996**, *23*, 11–20.
- (22) Pitard, B.; Aguerre, O.; Ariaux, M.; Lachages, A. M.; Bouknikachvilli, T.; Byk, G.; Dubertret, C.; Daniel, J. C.; Herviou, C.; Scherman, D.; Mayaux, J. F.; Crouzet, J. Submitted 1997. Virus-sized self assembling lamellar complexes between DNA and cationic micelles promote gene transfer. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, in press.
- (23) Makowski, M.; Rzeszotarska, B.; Smelka, L.; Kubica, Z. Debenzyloxycarbonylation and Detrifluoroacetylation of Dehydroalanine and Dehydrophenylalanine Peptides. *Liebigs Ann. Chem.* **1985**, 1457–1458.

JM9704964